A Phase 3, Randomised, Open-Label Study to Evaluate the Efficacy and Safety of 8 and 12 Weeks of Simeprevir (smv) Plus Sofosbuvir (sof) in Treatment-Naive and -Experienced Patients with Chronic Hcv Genotype 1 Infection Without Cirrhosis: Optimist-1